Zimmer Biomet's investment case hinges on its ability to convert earnings into cash with exceptional efficiency—operating cash flow reached 4.07x net income in 2026Q2—while navigating margin volatility and rising leverage. Revenue growth has stabilized in the ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth steadied at 4.8% in 2026Q2, yet gross margin dipped to 70.8% and operating margin fell to 15.0% from 17.9% in 2026Q1, reflecting SG&A rising to 41% of revenue and EPS volatility (33.8% YoY growth but a 41.7% decline in 2025Q4).
Zimmer Biomet is a global leader in orthopedic reconstructive implants, with strong positions in knee, hip, and shoulder replacements.
The company is advancing into higher-tech tools like robotics, data, and smart implants, as seen with the ROSA-assisted outpatient shoulder milestone.
Zimmer Biomet has demonstrated robust free cash flow generation, supporting its financial flexibility and shareholder returns.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $2.07+3.0% vs $2.01 | $2.2B+2.0% vs $2.1B |
Q2 2026 Apr 28, 2026 | $2.09+12.4% vs $1.86 | $2.1B+0.8% vs $2.1B |
Q1 2026 Feb 10, 2026 | $2.42+1.7% vs $2.38 | $2.2B+0.9% vs $2.2B |
Q4 2025 Nov 5, 2025 | $1.90+1.6% vs $1.87 | $2.0B-0.5% vs $2.0B |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zimmer Biomet (NYSE: ZBH - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings. Profitability This table compares Zimmer Biomet and CapsoVision's net
On September 08, 2026, Zimmer Biomet Holdings Inc (ZBH) shares fell 3.9% to a current price of $94.22. This decline comes amid a 52-week price range of $79.12 t
Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and Data WARSAW, Ind.
Benchmark ZBH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zimmer Biomet Holdings, Inc. (ZBH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $93.98 | $18.18B | 26.47 | 7.2% | 8.57% | 5.6% | 1.02% | |
| $275.07 | $105.45B | 32.75 | 11.16% | 14.43% | 16.36% | — | |
| $44.92 | $66.77B | 23.15 | 19.87% | 17.47% | 14.76% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — | |
| $27.50 | $11.55B | 19.10 | 6.09% | 9.2% | 21.18% | — | |
| $75.19 | $10.14B | 19.18 | 16.65% | 17.03% | 11.59% | — |
Zimmer Biomet Holdings, Inc. (ZBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Zimmer Biomet Holdings, Inc. (ZBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Aug 5, 2026·SEC
Jun 29, 2026·SEC
Get notified when ZBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zimmer Biomet Holdings, Inc. (ZBH) stock FAQ — growth, dividends, profitability & financials explained
Zimmer Biomet Holdings, Inc. (ZBH) reported $8.51B in revenue for fiscal year 2025. This represents a 806% increase from $939.0M in 1999.
Zimmer Biomet Holdings, Inc. (ZBH) grew revenue by 7.2% over the past year. This is steady growth.
Yes, Zimmer Biomet Holdings, Inc. (ZBH) is profitable, generating $806.8M in net income for fiscal year 2025 (8.6% net margin).
Yes, Zimmer Biomet Holdings, Inc. (ZBH) pays a dividend with a yield of 1.02%. This makes it attractive for income-focused investors.
Zimmer Biomet Holdings, Inc. (ZBH) has a return on equity (ROE) of 5.6%. This is below average, suggesting room for improvement.
Zimmer Biomet Holdings, Inc. (ZBH) generated $2.25B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
